We are developing an oral immunisation for SARS-CoV-2 in the fight against Coronavirus.
We are developing an app as part of Immubio that will enable individuals to build stronger immune systems and take control of their health.
We are developing a smart AI web app as part of Immuno® that will enable individuals to build stronger immune systems and take control of their health.
Still have further questions? Simply reach out to our team to discuss.Contact Us
Immubio is administered orally using liquid doses. For more information on administration, please see included instructions.
When it comes to efficacy, our immunisations offer a potential standout solution with far reaching benefits which we are planning to confirm with a global trial covering many countries. To learn more about our product approach, please visit our science section and request access to our Immubio scientific paper.
Safety is very important to our team and company. Immubio immunisations include no biological material, no heavy metals and no toxic chemicals and as such the probability of any toxic side effect or serious damage occurring as a result of our immunisations is extremely low. We are planning a global trial to confirm the safety of Immubio and will publish our results when available.
Our team have been focusing exclusively on our ImmubioCV immunisation for the novel Coronavirus and are selecting multiple sites for early stage trials. In time, immunisations for other infectious diseases are planned.
Immubio immunisations are planned to be produced in Germany in accordance with the highest modern standards. We are in discussions with multiple potential partners to establish our manufacturing capabilities.
Pending regulatory approval, our immunisations can be shipped globally and will available through direct purchase from Open Care by government agencies. If you are interested in accessing our immunisation product data sheets and our scientific paper, please contact us through our enquiry form on our contact page.
Still have further questions, simply reach out to our team to discuss.Contact Us